Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate Cancer

February 28th 2023

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Pembrolizumab Plus Standard Therapy Falls Short in mCRPC, EGFR-Mutant NSCLC Trials

February 28th 2023

The addition of pembrolizumab to standard therapies failed to improve survival outcomes in patients with metastatic castration-resistant prostate cancer in the KEYNOTE-641 trial and patients with EGFR-mutated non–small cell lung cancer in the KEYNOTE-789 trial.

Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate Cancer

February 23rd 2023

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

New Options Poised to Make a Splash in Metastatic Prostate Cancer

February 21st 2023

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer

February 21st 2023

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

New Technology Advances Prostate Cancer Care But Questions Linger

February 21st 2023

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Dr. Zhang on the Use of PARP Inhibitor–based Combinations in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care

February 21st 2023

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .

Dr. Ramnaraign on the Investigation of Atezolizumab Plus Tivozanib in CRPC

February 20th 2023

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Rucaparib Bests Physician's Choice for BRCA+ mCRPC

February 17th 2023

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

February 17th 2023

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Darolutamide Demonstrates Long-term Safety in nmCRPC

February 16th 2023

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC

February 16th 2023

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.

Talazoparib Plus Enzalutamide Improves rPFS in First-line mCRPC

February 16th 2023

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

February 16th 2023

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPC

February 14th 2023

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate Cancers

February 13th 2023

Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.

Dr. Ravi on Ongoing Investigation of PSMA-targeted Therapies in mCRPC

February 9th 2023

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC

February 8th 2023

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).